Salvage therapy with mycophenolate mofetil for lung transplant bronchiolitis obliterans: Importance of dosage

Transplantation

Volumn 64, Issue 3, 1997, Pages 533-535

  Speich, Rudolf ^a   Boehler, Annette ^a   Thurnheer, Robert ^a   Weder, Walter ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE;

ADULT; ARTICLE; BRONCHIOLITIS; CASE REPORT; CYSTIC FIBROSIS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG TRANSPLANTATION; PRIORITY JOURNAL; SALVAGE THERAPY;

ADULT; BRONCHIOLITIS OBLITERANS; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MYCOPHENOLIC ACID; SALVAGE THERAPY;

EID: 0030790350     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199708150-00027     Document Type: Article

References (13)

1. Chaparro C, Maurer JR, Chamberlain D, et al. Causes of death in lung transplant recipients. J Heart Lung Transplant 1994; 13: 758.
2. Scott JP, Higenbottam TW, Sharples L, et al. Risk factors for obliterative bronchiolitis in heart-lung transplant recipients. Transplantation 1991; 51: 813.
3. Reichenspurner H, Girgis RE, Robbins RC, et al. Obliterative bronchiolitis after lung and heart-lung transplantation. Ann Thorac Surg 1995; 60: 1845.
4. International Society for Heart and Lung Transplantation. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant 1993; 12: 713.
5. Novick RJ, Andreassian B, Schafers HJ, et al. Pulmonary retransplantation for obliterative bronchiolitis: intermediate-term results of a North American-European series. J Thorac Cardiovasc Surg 1994; 107: 755.
6. Afolabi OA, Parry G, Healy MD, Corris PA, Dark JH. The role of total lymphoid irradiation in the treatment of obliterative bronchiolitis: 2 years on. J Heart Lung Transplant 1996; 15 (suppl): S102.
7. Iacono AT, Keenan RJ, Duncan SR, et al. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Respir Crit Care Med 1996; 153: 1451.
8. Kesten S, Rajagopalan N, Maurer J. Cytolytic therapy for the treatment of bronchiolitis obliterans syndrome following lung transplantation. Transplantation 1996; 61: 427.
9. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321.
10. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients: U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225.
11. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: lung rejection study group. J Heart Lung Transplant 1996; 15: 1.
12. Boehler A, Vogt P, Zollinger A, Weder W, Speich R. Prospective study of the value of transbronchial lung biopsy after lung transplantation. Eur Respir J 1995; 9: 658.
13. Trulock EP, Ettinger NA, Brunt EM, Pasque MK, Kaiser LR, Cooper JD. The role of transbronchial lung biopsy in the treatment of lung transplant recipients: an analysis of 200 consecutive procedures. Chest 1992; 102: 1049.